Agios Pharmaceuticals, Inc. Forecast, price target & analysts
Agios Pharmaceuticals, Inc. Target price 2026 - Analyst rating & recommendation
Agios Pharmaceuticals, Inc. Classifications & Recommendation
Agios Pharmaceuticals, Inc. Price Target
| Target Price | $46.92 |
| Price | $33.07 |
| Potential |
41.88%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Agios Pharmaceuticals, Inc. 2027 .
The average Agios Pharmaceuticals, Inc. target price is $46.92.
This is
41.88%
register free of charge
$76.65
131.78%
register free of charge
$32.32
2.27%
register free of charge
|
|
| A rating was issued by 16 analysts: 12 Analysts recommend Agios Pharmaceuticals, Inc. to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Agios Pharmaceuticals, Inc. stock has an average upside potential 2027 of
41.88%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 54.03 | 186.16 |
| 48.03% | 244.55% | |
| EBITDA Margin | -864.26% | -212.55% |
| 24.91% | 75.41% | |
| Net Margin | -763.98% | -185.49% |
| 141.39% | 75.72% |
12 Analysts have issued a sales forecast Agios Pharmaceuticals, Inc. 2026 . The average Agios Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Agios Pharmaceuticals, Inc. EBITDA forecast 2026. The average Agios Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 Agios Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2026. The average Agios Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -7.12 | -5.79 |
| 161.17% | 18.68% | |
| P/E | negative | |
| EV/Sales | 7.29 |
12 Analysts have issued a Agios Pharmaceuticals, Inc. forecast for earnings per share. The average Agios Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Agios Pharmaceuticals, Inc....
Current Agios Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | Jul 31 2026 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Jul 31 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 30 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 21 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Jul 07 2026 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Jul 07 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Jul 31 2026 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Jul 31 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 30 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 21 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Jul 07 2026 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Jul 07 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
